The Download: whole-body rejuvenation drugs and five things to know about AI
MIT Technology Review reports on biologist David Sinclair's efforts to develop anti-aging drugs through chemical reprogramming. The newsletter also highlights OpenAI's confidential IPO filing and discusses key trends currently shaping the artificial intelligence landscape.
Why it matters
Advancements in longevity science and the potential public listing of a major AI firm like OpenAI represent significant shifts in both healthcare and the global technology economy.
Plus: OpenAI has confidentially filed for a US IPO.
The reporting focuses on technological developments and industry news without injecting political opinion or loaded language.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in